EAST RUTHERFORD, N.J., March 14, 2019 (GLOBE NEWSWIRE) -- Cambrex Corporation (NYSE: CBM), the leading small molecule company providing drug substance, drug product and analytical services across the entire drug lifecycle, today announced that it has completed the expansion of a new 150m2 research and development laboratory at its site in Paullo, Milan, Italy. In addition, Cambrex has installed a new 12,000 liter reactor into one of its cGMP manufacturing facilities at the site.
The R&D laboratory includes both chemistry and analytical development capabilities, with the installation of semi-automated glass lined reactors, as well as analytical instruments including multiple high and ultra-performance liquid chromatography, and gas chromatography systems, which have now been qualified and validated. To complement investments at other Cambrex sites, the new laboratory has also installed a flow chemistry system to allow for continuous manufacturing development.
The installation of the 12,000 liter reactor, along with the replacement of centrifuges with new, more efficient equipment in one of the site’s seven production departments, was part of a $3 million investment to upgrade and improve the efficiency of the plant which manufactures intermediates and generic APIs under GMP conditions.
“This investment is part of our ongoing strategy to ensure that the site can adapt to the growing and evolving needs of the generic API industry,” commented Aldo Magnini, Managing Director, Cambrex Milan. “Investing in key technologies such as continuous flow will allow us to look at new opportunities for the site to expand our portfolio of generic products, in a similar manner to the investment in highly potent API containment that we undertook in 2017, which allowed us to increase the number of new highly-potent oncology products in development.”
Cambrex manufactures over 70 generic APIs which are produced to cGMP standards at the Milan site, where the seven production departments are supported by a pilot plant, kilo-scale plant and development and analytical laboratories.
Cambrex is the leading small molecule company that provides drug substance, drug product and analytical services across the entire drug lifecycle. The company provides customers with an end-to-end partnership for the research, development and manufacture of small molecule therapeutics. With over 35 years’ experience and a growing team of over 2,000 experts servicing global clients from sites in North America and Europe, Cambrex is your trusted partner in branded and generic markets for API and dosage form development and manufacturing.
Cambrex offers a range of specialist drug substance technologies including biocatalysis, continuous flow, controlled substances, solid state science, material characterization and highly potent APIs. In addition, Cambrex can support conventional dosage forms including solids, semi-solids and liquids and also has the capability to manufacture specialist dosage forms such as solid dose, fixed dose, pediatric, bi-layer, stick packs, topicals, controlled substances, sterile and non-sterile dose forms. For more information, please visit www.cambrex.com.
Director, Marketing and Communications
Tel: +44 7803 443 155
Source: Cambrex Corporation